1.
Introduction. At present, it is not clear which of the three components of SSc pathogenesis is of primary importance or how they interrelate to cause the progressive fibrotic process. However, there has been a remarkable progress in the understanding of numerous basic mechanisms, which have shed light on the complex pathogenesis of the disease. 4 
Systemic Sclerosis (SSc

Are infectious agents involved in SSc pathogenesis?
The etiology of SSc is not known, however, it is currently accepted that the disease results from complex interactions between one or more environmental factors and a genetic predisposition in the host which eventually result in the development of severe, generalized, and often progressive tissue fibrosis .
It has been postulated that infectious agents may be the causative agents of autoimmune disorders including SSc and retroviruses and human cytomegalovirus (HCMV) among others, have been considered putative etiologic agents. This hypothesis is based on observations indicating that production of specific autoantibodies in SSc may be due to an antigen driven response triggered by "molecular mimicry" between self-antigens sharing structural similarities to a foreign protein of viral or bacterial origin. Thus, the autoantibodies may represent footprints of the elusive etiologic agent. In support of this hypothesis it was shown that sequence homologies exist between the p30 gag retroviral proteins of various feline and murine viruses and topoisomerase I, the marker SSc antigen recognized by anti-Scl-70 antibodies (1) .
Furthermore, antibodies to certain retroviral proteins have been found in sera from patients with SSc (2) . Despite these observations a more direct evidence of retroviral involvement in the etiology or pathogenesis of SSc is needed. Another putative etiologic agent for SSc is HCMV. The possible involvement of HCMV is supported by the observations of higher prevalence in patients with SSc of IgG anti-HCMV antibodies capable of binding the HCMV late protein UL94 and inducing apoptosis in human endothelial cells (3), an increased prevalence of IgA HCMV in patients positive for Scl-70 autoantibodies, the development of severe fibro-proliferative vascular changes in certain cases of HCMV infections, and the occurrence of autoantibodies recognizing the U1 snRNP primarily directed against a 70 kD 5 protein in patients with HCMV infections (4) . As is the case for retroviruses, there is no evidence to conclusively link HCMV infections with the development of SSc or with its clinical manifestations.
Contribution of genetic factors.
The contribution of genetic factors to the development and expression of SSc is strongly supported by: (1) the observation of familial clustering of the disease; (2) the high frequency of occurrence of other autoimmune disorders and autoantibody positivity in SSc family members;
(3) differences in SSc prevalence and clinical manifestations among different ethnic groups; and (4) the increased prevalence of certain human leukocyte antigen (HLA) and major histocompatibility complex (MHC) alleles among different ethnic groups and among patients with different types of disease or different patterns of autoantibodies (5 DQA1*1501, DQB1*0301, DRB1*0301, DQA1*0501, DQB1*0201. Certain patterns of disease expression also appear to be different among ethnic groups. For example, African American patients with SSc are more likely to be positive for anti-topoisomerase-1 antibodies, have worse disease manifestations with more pronounced systemic involvement and a higher frequency of pulmonary fibrosis. On the contrary, anti-centromere antibodies are more commonly seen in Caucasian patients who display more limited disease with less systemic manifestations (5, 6) .
In addition to providing a receptive environment for the development of SSc, genetic influences may also be involved in the phenotypic expression of the disease, thus, explaining the remarkable variability and the wide expression of clinical manifestations. In the case of SSc, these studies have been particularly focused on the potential influence of various genetic polymorphisms on the severity and progression of the fibrotic process by promoting increased collagen gene expression. In one study it was found that the presence of certain dinucleotide repeats in the upstream region of COL1A2 in patients with SSc resulted in its increased expression (7) . Another study has shown that two different single nucleotide polymorphisms in the gene for transforming growth factor  (TGF1), the potent profibrotic cytokine secreted from activated T-lymphocytes, are present in higher frequency in patients with SSc than in normal individuals (8) . Also, a study of Japanese and Choctaw Indians with SSc found that a single nucleotide polymorphism in the non-coding region of the fibrillin-1 gene at chromosome 15q was strongly related to the development of SSc in these patients (9) .
Although collectively these studies suggest an important contribution of genetic factors in the pathogenesis of SSc and, in particular, in the expression of specific SSc clinical subsets, at present, it appears more likely that genetic factors may provide a permissive environment that 7 allows either the initiation of the disease process or its progression and development of clinical manifestations.
Microchimerism: Does it play a role in SSc pathogenesis?
A novel hypothesis suggesting that allogenic fetal and maternal cells which cross the placenta during pregnancy may be involved in the pathogenesis of SSc has recently been proposed. Fetal or maternal cells persist in the maternal or offspring blood and tissues likely as a result of HLA II (DRB1) compatibility between the mother and the fetus (10) . It has been postulated that these engrafted fetal cells become activated by an environmental trigger and subsequently mount a graft-versus-host reaction towards the mother or offspring, which may result in the clinical symptoms of SSc. The identification of Y-chromosome sequences in the DNA obtained from skin biopsy specimens from female SSc patients who had previously given birth to male offspring provides strong support for this hypothesis (11) . Also, the recent demonstration of microchimerism of maternal origin in blood and tissues of the offspring might explain the occurrence of SSc in nulliparous women and in men. There is substantial controversy regarding this hypothesis since several recent studies have shown that fetal Y chromosome DNA is present in normal controls, although other studies have indicated that it may be the quantity and not the mere presence of fetal cells that may be the crucial contributory factor in the pathogenesis of SSc (12,13). Thus the intriguing and provocative hypothesis of microchimerism in the pathogenesis of SSc still remains controversial.
Humoral immune system alterations.
The presence of specific autoantibodies is one of the most common manifestations of SSc and greater than 90% of SSc patients have antinuclear antibodies in their serum. Numerous autoantibodies have been described in SSc patients ( Table 1) . Some of these are extremely 8 specific for SSc, whereas others are associated with different clinical manifestations of the disease.
Anti-Scl-70 antibodies were initially described to recognize a 70-kD nuclear protein (14) .
Subsequently, it was shown that these antibodies react with a 110-kD protein which has been identified as DNA topoisomerase I (15) . These antibodies are almost exclusively present in sera from patients with the diffuse form of SSc. About 30-40% of patients with diffuse SSc harbor these autoantibodies with a higher prevalence seen in African American patients. There are numerous cytokines which have been shown in in vitro studies to exert potent effects on the production and/or degradation of collagens (20) . However, it is very likely that the ultimate effects of these cytokines on fibroblast biosynthetic activities depend on their 10 concentration in the pericellular environment and on their relative proportions among a mixture of a large number of other cytokines which often have opposing effects on the target cells.
Anti
The TGF signaling pathway: A key component of pathologic tissue fibrosis.
Since the discovery of the potent profibrotic and immunomodulatory activities of TGF, this growth factor has been considered one of the most likely molecules involved in the pathogenesis of SSc (21) and other fibroproliferative diseases (22) , and a plethora of publications have described studies focused on this subject. Three functionally and structurally similar isoforms of TGF exist in humans and they play important roles in embryonic development, immune responses, and regulation of tissue repair following injury (23) . One of the most important effects of TGF is the stimulation of ECM synthesis evidenced by a remarkable increase in the production of numerous matrix molecules. TGF also decreases the synthesis of collagen-degrading metalloproteinases and stimulates the production of protease inhibitors such as tissue inhibitors of metalloproteinases-1 (TIMP-1).
Small amounts of TGF appear to sensitize fibroblasts and maintain them in a persistently activated state involving an autocrine mechanism which causes further production of TGF. Activated monocytes from SSc patients secrete TGF and the upregulation of this cytokine/growth factor appears to play a crucial role in the development of fibrosis in patients with SSc. It also appears that SSc fibroblasts express increased numbers of TGF receptors which might account for the increased TGF-induced signaling and the resulting increased collagen production in these cells. TGF is synthesized as a 390-412 amino acid pre-pro-TGF CTGF is another growth factor that appears also to play a crucial role in tissue fibrosis (28) . In addition to a potent profibrotic effect, CTGF also participates in angiogenesis, axial development of the musculoskeletal system, structural organization of connective tissue, and 
Alterations in the transcription of collagen genes.
A crucial element in the pathogenesis of SSc is the abnormal regulation of expression of the genes involved in the production and deposition of type I collagen, the most prevalent protein in fibrotic lesions from patients with SSc and the protein responsible for the most serious clinical manifestations of the disease. Numerous studies have shown that SSc fibroblasts display an increased expression of these genes which is determined at the transcriptional level. The upregulated transcriptional activity of collagen genes in SSc appears to be autonomous and is maintained even when cells are cultured in vitro for numerous passages. It is this persistent and autonomous upregulation of expression of collagen genes which distinguishes the process of normal wound healing from the disease state in SSc. The most important elements responsible for the regulation of expression of the genes encoding type I collagen are located in the 5'
promoter and first intron regions. There are numerous elements which exert enhancer or repressor functions on the overall transcriptional activity of these genes and are capable of regulating both the basal production of collagen as well as its production during pathologic conditions. Transcription factors are capable of specific binding to specific regulatory DNA sequences in the 5' promoter and in the first intron of collagen genes causing activation or 14 suppression of collagen gene expression. The transcription factors involved in the regulation of collagen gene expression are quite numerous and additional ones continue being identified and described (31) . Some of the most important and well-studied are listed in Table II. The CCAAT box, for example, is a regulatory region present in the promoter region of the genes encoding 1
and 2 chains of type I collagen (COL1A1 and COL1A2). Three different CCAAT binding factor proteins (CBF-A,B,C) may bind to this region and activate type I collagen transcription.
Another regulatory site is the Nuclear Factor-1 binding site, located in the proximal promoter region of COL1A1 and COL1A2. Nuclear Factor-1, an intranuclear regulatory protein, binds to these regions and also causes the activation of collagen gene expression. Sp1 is another intranuclear transcription factor which binds to a GC-rich region in the proximal promoter at sites near those recognized by NF1 and is a potent stimulator of collagen gene expression.
Elevated Sp1 and CBF binding to specific sequences in type I collagen genes has been demonstrated in SSc fibroblasts (32, 33) . These observations indicate the crucial role that these two transcription factors play in the development of tissue fibrosis in SSc. Another important transcription factor which has been recognized and characterized recently is C-Krox (34) . This protein appears to exert potent downregulation of collagen gene expression and, thus, may represent a counterbalance to Sp1 and CBF. The role of C-Krox in SSc, however, has not been determined. Alterations in either the transcription factors or their binding sites may directly relate to the pathogenesis of SSc, creating a mosaic of pathogenic possibilities that can be targeted with new therapies for SSc.
Endothelial cells and vascular alterations.
Vascular dysfunction appears to be one of the earliest clinical manifestations of SSc and it has been suggested to be a crucial initiating event in SSc pathogenesis (35) . The effects of vascular dysfunction in patients with SSc are most dramatic when they involve the pulmonary and renal arterioles, causing endothelial injury with subsequent intravascular thrombus formation as well as fibrous tissue deposition in the myointimal region of the vessels.
The constellation of these multiple vascular alterations leads to renal crisis and pulmonary hypertension, respectively, which are the most prevalent causes of morbidity and mortality in patients with SSc.
Conclusion.
Although a unified hypothesis encompassing all the components of SSc pathogenesis is sought, owing to the heterogeneity of the disease, the answer may lie not in a single pathway but in a constellation of different pathogenic mechanisms. A causative agent such as a virus of chemical substance may initiate tissue inflammation in a patient with a genetic predisposition for SSc. On the other hand, the initial event may be the engraftment of microchimeric cells after materno-fetal cell transfer with a subsequent graft-versus-host event. The pathogenesis of SSc as described above may follow a different path in individual patients although each of these pathways would lead to the same end results of altered humoral and cellular immunity, vascular endothelial lesions and, most importantly, excessive collagen deposition in skin and internal organs. Thus, a better understanding of the pathogenesis of SSc and the formulation of valid and testable hypotheses will undoubtedly provide the foundations to render reachable the goal of developing novel and effective therapeutic agents for this incurable disease. 
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